Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

SOUTH SAN FRANCISCO, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today provided a clinical update on voreloxin, its novel investigational drug candidate currently being developed in Phase 2 trials for acute myeloid leukemia (AML) and ovarian cancer. The clinical update coincides with the company's attendance at the 27th Annual JP Morgan Healthcare Conference in San Francisco.

"2008 was an important year for Sunesis, as we have continued to advance the development of voreloxin in both AML and ovarian cancer. We believe voreloxin has the potential to be a first-in-class anti-cancer agent for treating these diseases and potentially other hematologic and solid tumors," said Daniel Swisher, Chief Executive Officer and President of Sunesis. "We completed enrollment of our Phase 2 platinum-resistant ovarian cancer study and both of our ongoing AML studies are enrolling well, with 45 AML patients enrolled in the fourth quarter of 2008 alone. In the first half of 2009, we anticipate reporting additional data from all three of our ongoing voreloxin studies. We remain on track to initiate a pivotal voreloxin study in AML by the end of this year."

Sunesis is providing an update on the progress of its voreloxin clinical trials as follows:

Phase 2 and 1b/2 Studies of Voreloxin in AML

Sunesis is evaluating single agent voreloxin in an ongoing Phase 2 trial, known as REVEAL-1, in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy. Interim results recently presented at the 50th Annual Meeting of the American Society of Hematology (ASH) show that voreloxin induces complete remissions in these poor risk patients. At ASH, outcome for the 29 patients enrolled and treated with Schedule A, 72 mg/m2 of vo
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015  Neogen Corporation (NASDAQ: NEOG ) announced ... United Kingdom -based Lab M Holdings, a ... diagnostic systems. Lab M was founded ... of microbial testing and diagnostic products for the global ... currently sells into more than 70 countries worldwide, and ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based ... down the product choices to a manageable shortlist of bench and floor scales ... models that fit best with the customer’s industry and application. , Side-by-side ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3METTLER TOLEDO Updates Online Scale Selection Tool 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... , , ... ... ... , ...
... ... information on fertilizers, soil fertility and the critical agricultural issues that face Africa, has ... ... March 3, 2010 -- AfricaFertilizer.org , a global forum to disseminate and exchange ...
... ... , ... , , , ... ...
Cached Biology Technology:Anavex comments on failure of Pfizer and Medivation's Alzheimer's investigational drug Dimebon during Phase 3 clinical trials 2Anavex comments on failure of Pfizer and Medivation's Alzheimer's investigational drug Dimebon during Phase 3 clinical trials 3Anavex comments on failure of Pfizer and Medivation's Alzheimer's investigational drug Dimebon during Phase 3 clinical trials 4AfricaFertilizer.org to Increase Agricultural Productivity and Knowledge Across the African Continent 2AfricaFertilizer.org to Increase Agricultural Productivity and Knowledge Across the African Continent 3AfricaFertilizer.org to Increase Agricultural Productivity and Knowledge Across the African Continent 4Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health 2Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health 3Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health 4Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health 5
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... could lead to improved varieties of the crop most ... Scientists funded in part by the Biotechnology and Biological ... to uncover key genes that control the specific characteristics ... out at the Scottish Crop Research Institute, Birmingham University ...
... of birds. Without them, birds could not fly or ... Experimentally testing one current hypothesis, developmental biologists at University ... answer. , In a previous study, UW anatomy professor ... hedgehog (Shh) and bone morphogenetic protein 2 (Bmp2) must ...
... are more likely to bounce back from extreme coastal ... knowledge, according to a report published in Science. , ... valuable insight into handling extreme coastal disasters - inevitable ... by 2030 and global warming continues to exacerbate extreme ...
Cached Biology News:Whisky fans can drink to crop research 2Molecular mechanism of feather formation found 2Molecular mechanism of feather formation found 3Environmental lessons from tsunami as world's coastal population doubles 2
...
...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
... recombinant human angiogenin expressed in ... Physical form: Lyophilized from a ... phosphate buffered saline. Titertest ... Titertest values: capture ELISA ...
Biology Products: